ResMed CFO Retires After 27 Years; Exact Sciences Executive Takes Over
Event summary
- ResMed CFO Brett Sandercock retires May 4, 2026 after 27 years, including 20 as CFO.
- Aaron Bloomer appointed successor, joining from Exact Sciences where he was CFO.
- Bloomer brings 17+ years of global finance experience, including roles at Baxter and 3M.
- Sandercock will serve as advisor to CEO through end of 2027.
- ResMed reiterates FY2026 outlook: gross margin 62-63%, SG&A 19-20%, R&D 6-7%, tax rate 21-23%.
The big picture
ResMed's CFO transition comes as the company pushes its 2030 strategy, aiming to scale its digital health solutions. The move reflects a broader trend in healthcare technology toward operational rigor and strategic growth. Bloomer's background suggests ResMed may prioritize margin expansion and capital allocation frameworks similar to those he implemented at Exact Sciences.
What we're watching
- Strategic Alignment
- How Bloomer's experience in cancer diagnostics will translate to ResMed's sleep and respiratory focus.
- Operational Discipline
- Whether Bloomer can maintain ResMed's financial discipline while scaling its 2030 strategy.
- M&A Activity
- The pace at which Bloomer may pursue acquisitions to expand ResMed's portfolio, given his M&A experience.